Nikhil C. Munshi, MD; Herve Avet-Loiseau, PhD; Andy C. Rawstron, PhD; et al.
free access
JAMA Oncol. 2017;3(1):28-35. doi:10.1001/jamaoncol.2016.3160
This meta-analysis examines the prognostic value of minimal residual disease assessment as associated with survival outcomes in patients with newly diagnosed multiple myeloma.
-
Editorial
Minimal Residual Disease as a Potential Surrogate End Point鈥擫ingering Questions
Nicole J. Gormley, MD; Ann T. Farrell, MD; Richard Pazdur, MD
JAMA Oncol
Tehillah S. Menes, MD; Karla Kerlikowske, MD; Jane Lange, PhD; et al.
free access
JAMA Oncol. 2017;3(1):36-41. doi:10.1001/jamaoncol.2016.3022
This cohort study uses data from the Breast Cancer Surveillance Consortium to evaluate the 10-year cumulative risk of breast cancer in women with atypical ductal hyperplasia that was diagnosed on needle biopsy vs excisional biopsy.
Conny Vrieling, MD, PhD; Erik van Werkhoven, MSc; Philippe Maingon, MD, PhD; et al.
free access
has audio
JAMA Oncol. 2017;3(1):42-48. doi:10.1001/jamaoncol.2016.3031
This reanalysis of the EORTC 鈥渂oost vs no boost鈥� trial examines the long-term impact of prognostic factors on ipsilateral breast tumor recurrence in patients treated with breast-conserving therapy.
-
Podcast:
Prognostic Factors for Local Control in Breast Cancer With Boost vs No Boost (JAMA Oncology)
-
Editorial
Who Benefits From a Tumor Bed Boost After Whole-Breast Radiotherapy?
Laurie W. Cuttino, MD; Charlotte Dai Kubicky, MD, PhD
JAMA Oncol
Kevin T. Nead, MD, MPhil; Greg Gaskin, BS; Cariad Chester, BS; et al.
free access
has audio
JAMA Oncol. 2017;3(1):49-55. doi:10.1001/jamaoncol.2016.3662
This cohort study uses clinical informatics to examine the association of androgen deprivation therapy for prostate cancer with the development of dementia.
-
Podcast:
Association Between Androgen Deprivation Therapy and Risk of Dementia (JAMA Oncology)
-
Invited Commentary
Observational Cohort Studies and the Challenges of In Silico Experiments
Colin G. Walsh, MD, MA; Kevin B. Johnson, MD, MS
JAMA Oncol
Peter W. Szlosarek, MD, PhD; Jeremy P. Steele, MD; Luke Nolan, MD, PhD; et al.
free access
JAMA Oncol. 2017;3(1):58-66. doi:10.1001/jamaoncol.2016.3049
This phase 2 randomized clinical trial examines the effect of arginine deprivation plus best supportive care vs best supportive care alone in patients with argininosuccinate synthetase 1鈥揹eficient malignant pleural mesothelioma.
-
Invited Commentary
The ADAM Trial: Visiting the Road Less Traveled
Surein Arulananda, MBBS; Thomas John, MBBS, PhD, FRACP
JAMA Oncol
Ellen S. de Morrée, MSc; Nicholas J. Vogelzang, MD; Daniel P. Petrylak, MD; et al.
free access
JAMA Oncol. 2017;3(1):68-75. doi:10.1001/jamaoncol.2016.3000
This study uses data from a clinical trial comparing docetaxel vs mitoxantrone for metastatic castration-resistant prostate cancer to investigate the association between the number of docetaxel cycles and overall survival in patients who benefitted from docetaxel.
J. Alejandro Rauh-Hain, MD; Alexander Melamed, MD, MPH; Alexi Wright, MD, MPH; et al.
free access
JAMA Oncol. 2017;3(1):76-82. doi:10.1001/jamaoncol.2016.4411
This study uses the US National Cancer Database to compare overall survival following primary cytoreductive surgery vs neoadjuvant chemotherapy in women with advanced-stage epithelial ovarian cancer.
Yong Yang, MD; Jian-Zhong Cao, MD; Sheng-Min Lan, MD; et al.
free access
JAMA Oncol. 2017;3(1):83-91. doi:10.1001/jamaoncol.2016.5094
This cohort study assesses whether improved locoregional control is associated with a survival benefit in patients with early-stage extranodal natural killer/T-cell lymphoma in China.
Ronald M. Epstein, MD; Paul R. Duberstein, PhD; Joshua J. Fenton, MD, MPH; et al.
free access
JAMA Oncol. 2017;3(1):92-100. doi:10.1001/jamaoncol.2016.4373
This study describes the effectiveness of a combined intervention that included oncologist communication training and coaching for patients with advanced cancer and caregivers in improving patient-centered communication.